User-defined protein marker assay development for characterization of circulating tumor cells using the CellSearch® system.
The majority of cancer-related deaths result from metastasis, which has been associated with the presence of circulating tumor cells (CTCs). It has been shown that CTC cut-off values exist that predict for poorer overall survival in metastatic breast (≥5), prostate (≥5), and colorectal (≥3) cancer based on assessment of 7.5 ml of blood. Development of the CellSearch® system (Veridex) has allowed for sensitive enumeration of CTCs. In the current study, protocols were developed and optimized for use with the CellSearch system to characterize CTCs with respect to user-defined protein markers of interest in human blood samples, including the cancer stem cell marker CD44 and the apoptosis marker M-30. Flow cytometry (FCM) experiments were initially carried out to assess expression of CD44 and M-30 on MDA-MB-468 human tumor cells. Human blood samples were then spiked with MDA-MB-468 cells and processed with the appropriate antibody (CD44/M-30) on the CellSearch. Detailed optimization of CD44 was carried out on the CellSearch using various antibody concentrations, exposure times, and cell lines with varying CD44 expression. Troubleshooting experiments were undertaken to explain observed discrepancies between FCM and CellSearch results for the M-30 marker. After extensive optimization, the best CD44/M-30 concentrations and exposure times were determined to be 1.5/3.5 μg/ml and 0.2/0.8 s, respectively. The percentage of CD44(+) tumor cells was 99.5 ± 0.39% by FCM and 98.8 ± 0.51% by the CellSearch system. The percentage of M-30(+) tumor cells following paclitaxel treatment was 17.6 ± 1.18% by FCM and 10.9 ± 2.41% by CellSearch. Proper optimization of the CD44 marker was achieved; however, M-30 does not appear to be a suitable marker for use in this platform. Taken together, the current study provides a detailed description of the process of user-defined protein marker development and optimization using the CellSearch, and will be an important resource for the future development of protein marker assays by users of this platform.
London Regional Cancer Program, London Health Sciences Centre, London, Ontario, Canada.
Lori E
LE
Lowes
Benjamin D
BD
Hedley
Mike
M
Keeney
Alison L
AL
Allan
D017209:Apoptosis; D014408:Biomarkers, Tumor / Q000032:analysis*; D002452:Cell Count / Q000379:methods; D045744:Cell Line, Tumor / Q000187:drug effects; D002465:Cell Movement; D005434:Flow Cytometry; D049452:Green Fluorescent Proteins; D006801:Humans; D018960:Hyaluronan Receptors / Q000032:analysis; D053538:Keratin-18 / Q000032:analysis; D009362:Neoplasm Metastasis / Q000175:diagnosis; D009363:Neoplasm Proteins / Q000032:analysis*; D014411:Neoplastic Stem Cells / Q000473:pathology; D017239:Paclitaxel / Q000494:pharmacology; D010446:Peptide Fragments / Q000032:analysis; D011933:Reagent Kits, Diagnostic / Q000592:standards*; D012680:Sensitivity and Specificity; D012984:Software; D013997:Time Factors
D014408:Biomarkers, Tumor; C497483:CD44 protein, human; D018960:Hyaluronan Receptors; D053538:Keratin-18; C561463:M30 cytokeratin-18 peptide, human; D009363:Neoplasm Proteins; D010446:Peptide Fragments; D011933:Reagent Kits, Diagnostic; C485184:enhanced green fluorescent protein; D049452:Green Fluorescent Proteins; D017239:Paclitaxel